Ryan also brings up a good point to bring up the fact that GHRH receptors are typically not desensitized with higher dosing but again not much accomplished with CJC-1295, ,MOD GRF 1-29 where we know the 100mcg is a saturation dose. on the other hand we can desensitize the GHRP receptor if we start increasing the dosing significantly above the saturation dosing of 100mcg. I think you are fine at a 150 mcg dosing but again how much more benefit are you really getting.
There were no significant changes in IGF-1 values observed during 24 hours following any AOD9604 dose compared with placebo. No significant differences in glucose levels were observed following AOD9604 administration compared with placebo with the exception of one isolated time point (8% increase 12 hour post treatment in one subject receiving 54 mg AOD09604). There were no clinically significant observable trends in vital signs, physical examinations, abnormalities noted in the ECG measurements, or findings in the safety-related laboratory tests throughout the study.
WT (n = 9) and β3-KO (n = 9) mice were used in this study. Animals were fasted 2 h before being individually placed in an indirect calorimeter. Calorimetry was performed as in previous studies (8). After baseline readings were taken, mice were injected with one of the following compounds: saline (control; n = 3); AOD9604 (2 mg/kg body weight; n = 3); or BRL37344 (250 μg/kg body weight; n = 3). Rates of energy expenditure, fat oxidation, and glucose oxidation were measured for an additional 30 min. The concentrations of AOD9604 and BRL37344 were determined as lowest concentration needed to give a maximal response in these mice (data not shown). Rates of energy expenditure and fat and glucose oxidation were plotted as a change from the average baseline values.
In the multiple dose and long term studies, AOD9604 was well tolerated over the entire dose range. In none of the studies did any drug-related withdrawals or drug-related serious AEs occur. No drug related clinically significant AEs, or changes of clinical significance in vital signs, safety laboratory tests or ECGs were detected during the studies. There were no observable trends in the incidence of AEs between the 0.25 mg, 0.5 mg, 1 mg, 9 mg and 27 mg AOD9604 and placebo treatment groups. The highest dose administration (54 mg), however, was associated with an increased incidence of GI-related AEs.
The natriuretic peptide system, the primary salt‐excreting system in humans, acts as an endogenous antagonist of the renin‐angiotensin‐aldosterone system.9 The primary circulating natriuretic peptides are atrial natriuretic peptide (ANP) and B‐type natriuretic peptide (BNP).10 ANP is produced primarily in the atria, while BNP is derived from both the atria and the ventricles.10, 11
IGF-1 is the only natural hormone that can stimulate lean muscle mass gains and help the body choose to burn stored fat over simple glucose for fuel, meaning, you will burn off more fat. Studies demonstrate that only colostrum supplements containing lactoferrin can produce lean muscle gains that complement IGF-1 supplementation. That’s because it is actually the lactoferrin in some brands of colostrum that work to increase muscle mass and to burn adipose tissue. In fact, in a recent 2013 study, participants who supplemented with lactoferrin over a period of eight weeks experienced increased weight loss, reduced visceral and subcutaneous fat, reduced waist circumference, and reduced hip circumference.
Prolonged use of intact hGH may result in negative effects on glucose metabolism, such as glucose intolerance and insulin resistance. Given that AOD9604 is a peptide fragment of the C-terminus of hGH, its effect on glucose control was monitored. OGTT testing was carried out on all patients during the screening phase as well as at various time points during the treatment period. No significant changes or obvious trends in the OGTT in any treatment group were observed, suggesting that AOD9604 supplementation does not deteriorate glucose control or induce insulin resistance. In contrast, treatment with AOD9604 seemed to have a positive effect in subjects with impaired glucose tolerance. In the 12 weeks treatment study, patients with impaired glucose tolerance supplemented with AOD9604 were less likely to develop diabetes during the study than subjects taking placebo. This hypothesis, however, has to be confirmed in a separate clinical trial. In contrast, in a recent clinical trial of hGH effects in obese women, hGH caused an increase in IGF-1 levels over a 6 month dosing period and decreased glucose tolerance in a subset of trial participants .
The objective of the 3rd study (METAOD003) was to assess the safety, tolerability and pharmacodynamics of single oral doses of AOD9604 in healthy, clinically obese males. 17 subjects (n = 15 completed the study), age 35 to 54 years, with a BMI ≥ 35 kg/m2 (range 35 to 56 kg/m2) subsequently received 3 increasing doses of AOD9604 (9, 27 and 54 mg) or placebo. Each dose administration was separated by a 2-week wash-out period.
The T α 1 peptide can be administered via subcutaneous injection or as a transdermal cream. T α 1 has been found to be very safe, and there have not been any documented side effects associated with its administration. It is approved in more than 37 countries for the treatment of hepatitis B, hepatitis C, and as an adjunct to chemotherapy and various vaccines.
The most potent weight loss peptide is HGH Fragment 176-191 which is the part of the Growth Hormone molecule responsible for fat burning. In HGH Frag Studies, it has been proven to reduce body fat, particularly in the abdominal area. The second most potent fat loss peptide is CJC-1295 DAC since it causes the overall GH level to rise in the body (the opposite of what happens naturally as a person gets older, which is why people tend to put on weight as they age). If your only goal is fat loss, it's often best to avoid the use of GHRP products (GHRP-6, GHRP-2 or Ipamorelin) since they can stimulate hunger and/or raise cortisol, both of which can be counterproductive to fat burning.
I have questions about combined therapy of CJC 1295 and Ipamorelin at the same time on a daily basis for both. The compounding pharmacies do not clearly state whether the CJC is with or without DAC. If it is the CJC with DAC, which sustains elevated GH and IGF-1 for several days, would taking it nightly in conjunction with the Ipramorelin, that is suggested to be taken TID but is being recommended only once at night, be over-stimulatory? If the CJC is without DAC, why take two pepetides simultaneously ,that have similar effects? I am just not clear why taking a daily dose of CJC with Ipamorelin as a single dose is better than taking the CJC with DAC twice per week alone or take the CJC with DAC for a while then switch to the Ipamorelin for a while?
These “protein chains”, are not just turned to by gym junkies for their muscle synthesising and fat burning properties. With peptides for injury recovery and repair, cognition, anti-aging, sleep, tanning, improving libido, or anxiety, to name a few, this growing market caters for everyone. Unfortunately, there has been a lot of stigma in the public eye due to media and press, shaming their use and clouding potential in debilitating chronic conditions such as obesity, muscle atrophy, osteoarthritis, dementia, Alzheimer’s or even recovery post stroke.
When taking Ipamorelin, you want it to be pushed through your system naturally, and at the same levels. If you are constantly altering the times you take it, or increase/decrease dosages during your cycle, this is not going to be attainable. To maximize the benefits and gains you are going to experience, dosage levels should be consistent, as should the timing of the dosage you are taking each day.
Human Growth Hormone (hGH) is not only important for growth processes during childhood, but plays a pivotal role in lipid metabolism throughout life. It is well known that hGH is involved in the regulation of lipolysis and lipogenesis. Therefore, hGH was implicated as a good potential candidate for the treatment of obesity. However undesired side effects, such as induction of glucose intolerance and insulin resistance, diabetes, acromegaly, cancer, edema, and hypertension [10-13] rendered therapeutic doses of hGH unsuitable for long-term treatments in humans.
All studies were performed according the Declaration of Helsinki (as amended in Edinburgh, Scotland, October 2000) and the ICH Guidelines for Good Clinical Practice (GCP) (E6). Further, independent ethics review committees of up to 16 Australian hospitals and medical centers have approved each of them. The two largest studies (METAOD005 and METAOD006) were registered at the Therapeutic Goods Administration’s Clinical Trial Notification (CTN) Scheme in Australia.
Results: AOD9604 had no effect on serum IGF-1 levels, which confirms the hypothesis that AOD9604 does not act via IGF-1. Results of oral glucose tolerance test demonstrated that, in contrast with hGH, AOD9604 has no negative effect on carbohydrate metabolism. There were no anti-AOD9604 antibodies detected in any of the patients selected for antibody assay. In none of the studies did a withdrawal or serious adverse event occur related to intake of AOD9604.
If you are interested in using fat loss supplements to assist in your weight loss journey but have never used peptides before, don’t worry, our clinic doctor is available to answer any of your questions. To discuss any concerns, simply email your questions to email@example.com and our doctor and professional team will get back to you so you can be one step closer to starting your weight loss journey. Want to find out more information right now? Why not see if your questions have already been answered in our FAQs?
The discovery of the role of Tβ4 in the process of immune regulation has lead to its use as a valuable therapeutic agent. Tβ4 has been used in the treatment of HIV, AIDS, Influenza, colds, and various infections. It has been utilized in the management of various inflammatory conditions, as well as part of treatment following heart attack due to its cardio and neuroprotective effects.
Over the last 40 years a lot of research has been done on various peptides developing new peptide sequences to produce new peptides with fewer side effects and new beneficial effects. For example fragments of the growth hormone peptide have been developed such as AOD 9604 which possess all the fat burning properties of growth hormone without any of its adverse effects on blood sugar or growth.